For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ABIOMED been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

ABIOMED is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ABMD is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for ABMD's full-year earnings has moved 3.01% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Our latest available data shows that ABMD has returned about 68.72% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 0.30% on average. As we can see, ABIOMED is performing better than its sector in the calendar year.

Looking more specifically, ABMD belongs to the Medical - Instruments industry, which includes 93 individual stocks and currently sits at #72 in the Zacks Industry Rank. This group has gained an average of 11.55% so far this year, so ABMD is performing better in this area.

Investors with an interest in Medical stocks should continue to track ABMD. The stock will be looking to continue its solid performance.